Study Complete
Sponsor ID
20130240
Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in FrancePILOTE
Study Details
The purpose of the study is to describe the characteristics and management of post menopausal women with osteoporosis treated with Prolia in France, and examine the use of Prolia in routine clinical practice in France
Protocol Summary
Primary Outcome Measures
patient occurence of persistence (persistence is defined in the outcome description) at 12 months
Timeframe: 12 months
Secondary Outcome Measures
patient occurence of persistence (persistence is defined in the outcome description) at 24 months and time to non-persistence at 24 months
Timeframe: 24 months
describe the use of Prolia in routine clinical practice during approximately 30 months from the first injection
Timeframe: 30 months from first injection
patient occurence of Adverse Drug Reactions (ADRs) and Serious Adverse Drug Reactions (SADRs) as collected in routine clinical practice
Timeframe: 30 months or early termination
Occurrence of patient reported osteoporosis related vertebral and non vertebral fractures reported during the study
Timeframe: 30 months or early termination
Locations
Location
Amgen
Paris, France, 92200
Status
Recruiting